Newron Pharmaceuticals - Sarizotan fails to shine
On 4 May Newron Pharmaceuticals announced that the pivotal Rett syndrome STARS study of sarizotan had not met the primary or any secondary...
125 Views
Newron Pharmaceuticals - Seeing STARS
The statistical analysis plan for the pivotal STARS trial of sarizotan for symptomatic treatment of Rett syndrome should be FDA approved soon. This...
631 Views
Newron Pharmaceuticals - Xadago sales slow but STARS ahead
Newron Pharmaceuticals’ recently reported interim results highlight that despite additional worldwide launches of Xadago, sales growth in the US...
839 Views
Newron Pharmaceuticals - Xadago slows, Evenamide lags but STARS ahead
Newron Pharmaceuticals’ interim results highlight that despite additional worldwide launches of Xadago, sales growth in the US and Europe remain...
1.2k Views
Newron Pharmaceuticals - 2018 focus on the CNS pipeline
Xadago for Parkinson’s disease (PD) is now available in 14 European countries through partner, Zambon. Additionally, the drug is available in the...
145 Views